How Alloy is Enabling the Discovery and Engineering of Chimeric Antigen Receptors for Cell Therapies
Alloy Therapeutics enables high-throughput CAR discovery and engineering by providing diverse binder sets from its ATX-Gx™ and ATX-SiD platforms to optimize antigen specificity and affinity. Their Discovery Services offer comprehensive functional screening in primary immune cells—including expression, activation, and cell-killing assays—to streamline the development of next-generation CAR-T, NK, and macrophage therapies. Cell therapy utilizing chimeric […]
How Enabling Drug Delivery Innovation Gets Better Medicines to Patients
Alloy Therapeutics is democratizing access to foundational drug delivery, formulation, and half-life extension technologies to overcome critical barriers such as molecular stability and crossing the blood-brain barrier. Through its Innovation Subscription model and collaborations with institutions like MIT’s Marble Center, Alloy provides the drug discovery community with validated, pre-competitive delivery platforms including LNPs and antibody-drug […]
How Alloy is Democratizing T Cell Receptor (TCR) Therapy Discovery
At Alloy Therapeutics our goal is to empower drug discovery teams with technologies and services enabling them to make the best medicines for patients. Our company started this work in antibodies with a long-term plan to expand innovation to “adjacent modalities” that require similar expertise and could leverage much of our core antibody discovery, protein […]
How Our Mytide Investment Supports the Peptides Ecosystem
Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning
Alloy Therapeutics led a $7 million Series A for Mytide Therapeutics to scale its AI-enabled Gen2 platform, which uses machine learning to accelerate peptide manufacturing by 30x. This technology enables the rapid, high-purity production of complex natural and non-natural peptides for therapeutic discovery and personalized peptide vaccines (PPV). Biotech ecosystem company Alloy Therapeutics leads the […]
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
Alloy Therapeutics has enhanced its antibody discovery ecosystem by acquiring deepCDR Biologics, integrating advanced bioinformatics and deep learning capabilities into Alloy Discovery Services. This acquisition enables the rapid identification of high-affinity antibody candidates through machine learning-guided protein engineering and proprietary mammalian display technologies. The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery […]
Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics
Wheeler Bio is a biomanufacturing company co-founded by Alloy Therapeutics and Echo Investment Capital to accelerate antibody therapeutics from discovery to IND. Operating out of Oklahoma City and Boston, Wheeler integrates cGMP manufacturing with Alloy’s discovery ecosystem to provide emerging biopharma companies a predictable, high-speed path to clinical trials. BOSTON, MA & OKLAHOMA CITY, OK, […]
Vernal Biosciences Launches to Democratize Access to High Quality mRNA Manufacturing
Seed Financing Will Scale Company’s Technology and Business Operations to Serve Clients of All Stages Vernal Biosciences launched with seed financing led by Alloy Therapeutics to democratize access to high-purity mRNA manufacturing for research and clinical-stage programs. Led by mRNA veteran Christian Cobaugh, Vernal provides a scalable manufacturing platform within the Alloy biotechnology ecosystem to […]